Syros Pharmaceuticals (SYRS) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Syros Reports Third Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
November 12, 2019 8:00 AM ESTPresented New Clinical Data from Phase 2 Study of SY-1425 in RARA-Positive Newly Diagnosed Unfit AML Patients at ESH Conference
Presented New Preclinical Data on SY-5609 at AACR-NCI-EORTC Conference
On Track for Key 2020 Milestones, Including Potential Proof-of-Concept Data for SY-1425 in RARA-Positive Relapsed or Refractory AML and Initiation of Phase 1 Trial of SY-5609
Management to Host Conference Call at 8:30 a.m. ET Today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in... More
